Itraconazole: A Comprehensive Guide for API Importers, Manufacturers, and Compounding Pharmacies
The pharmaceutical family is constantly evolving and expanding, driven by innovative APIs that address the health issues they aim to overcome.
For API importers, drug manufacturers, and compounding pharmacies, taking Itraconazole into your inventory is not just an advantage—it’s a necessity for your business growth and diversity.
Itraconazole remains a cornerstone of systemic antifungal therapy, representing a robust and reliable market segment with consistent demand.
This comprehensive guide is your definitive resource on Itraconazole API.
We move beyond basic pharmacology to deliver the critical, in-depth intelligence you need to make informed decisions.
Whether you’re evaluating your supply chain, developing a new formulation, or planning a compounding strategy, this post provides the technical data, market analysis, and strategic insights to position your operations for success in the stable and growing Itraconazole market.
What is Itraconazole?
Itraconazole is a broad-spectrum, synthetic triazole antifungal agent.
As a triazole antifungal, Itraconazole inhibits a key enzyme in the fungal ergosterol biosynthesis pathway.
Its core structure features a triazole ring, which is essential to its mechanism of action because it binds to the fungal cytochrome P450 enzyme system.
For industry professionals, its key differentiators are:
Broad-Spectrum Activity: It is effective against a wide range of pathogenic fungi, including dermatophytes, yeasts (e.g., Candida spp.), and molds (e.g., Aspergillus spp.), making it exceptionally versatile for drug development.
High Lipophilicity: This property enables excellent penetration into tissues, skin, and nails, resulting in high concentrations at the site of infection and facilitating its use for difficult-to-treat conditions, such as onychomycosis.
Extensive Post-Antifungal Effect: It continues to suppress fungal growth even after plasma concentrations have fallen, due to its persistence in tissues, which can be a valuable point in dosage form design and patient compliance.
Understanding these core characteristics is the first step in appreciating its market potential and technical handling requirements.
What are the brand names of Itraconazole?
The most well-known global brand name for Itraconazole is Sporanox®, initially developed by Janssen Pharmaceutical.
API buyers and compounders should note that, while Sporanox is the branded product, the API is universally referred to as Itraconazole.
As the patent has long expired, the market is dominated by generic manufacturers.
Other brand names exist worldwide, including but not limited to:
Itrasys
Itrazen
Itrizole
Orungal
Sopronax
When sourcing Itronazole API, using the CAS Number 84625-61-6 and the compendial names (USP/EP) is the best practice to ensure precision in chemical procurement and avoid confusion.
What is Itraconazole used for?
Itraconazole is approved for a wide range of fungal infections, making it one of the most versatile antifungal agents on the market.
Its indications can be categorized as follows:
Superficial Fungal Infections:
Onychomycosis: Fungal infections of the toenails and fingernails. It is a first-line systemic treatment, often administered via “pulse therapy” (e.g., 200 mg twice daily for one week per month).
Dermatophytoses: Infections like tinea corporis (ringworm), tinea cruris (jock itch), and tinea pedis (athlete’s foot).
Pityriasis Versicolor: Caused by Malassezia furfur.
Oral and Oesophageal Candidiasis: Particularly in immunocompromised patients.
Systemic Fungal Infections (Mycoses):
Aspergillosis: Both pulmonary and extrapulmonary.
Candidiasis: Systemic infections, including chronic disseminated candidiasis.
Cryptococcosis: Including cryptococcal meningitis (often as maintenance therapy in HIV patients).
Histoplasmosis, Blastomycosis, Paracoccidioidomycosis, Sporotrichosis: Endemic mycoses.
For Compounding Pharmacies: Understanding its off-label uses is key. There are plenty of opportunities for creating custom dosage forms for specific needs, such as:
Veterinary Medicines: Used in antifungal treatments for animals, particularly for dermatophytosis in pets.
Custom Oral Suspensions: For pediatric patients or those with swallowing difficulties, where commercial formulations are not suitable or available.
Topical Formulations: While not standard, there is experimental and compounding interest in creams or solutions for localized infections.
Can Itraconazole Treat Candida?
Yes, absolutely.
Itraconazole is a first-line agent for both mucocutaneous and systemic Candida infections.
Its efficacy against various Candida species is a cornerstone of its utility. However, it is crucial to understand the spectrum:
Highly Susceptible: Candida albicans, C. parapsilosis, C. tropicalis.
Dose-Dependent Susceptibility or Potential Resistance: Candida glabrata.
Often Resistant: Candida krusei.
For oropharyngeal and esophageal candidiasis, Itraconazole oral solution is particularly effective due to its superior mucosal absorption compared to the capsule formulation.
For systemic candidiasis, it remains a viable alternative to fluconazole and echinocandins, especially in specific clinical scenarios.
For Manufacturers: Its broad antifungal activity ensures consistent, widespread demand for the API in formulations targeting these prevalent infections.
How Itraconazole works? (Mechanism of Action)
Understanding the Mechanism of Action (MoA) is vital for manufacturers and compounders to appreciate stability concerns, potential interactions, and the rationale for use.
Inhibition of Ergosterol Synthesis: The primary mechanism of Itraconazole, like other azoles, is the inhibition of a fungal cytochrome P450-dependent enzyme called lanosterol 14-α-demethylase.
Disruption of Cell Membrane Integrity: This enzyme is essential for the conversion of lanosterol to ergosterol. Ergosterol is a critical and unique component of the fungal cell membrane, providing structural integrity and fluidity.
Fungal Cell Death: The depletion of ergosterol and the simultaneous accumulation of toxic methylated sterol precursors disrupt membrane function. This leads to increased membrane permeability, inhibition of growth, and ultimately, the death of the fungal cell.
Key Differentiator from Older Azoles: Itraconazole’s higher affinity for fungal cytochrome P450 enzymes compared to mammalian enzymes contributes to its selective toxicity and improved safety profile over older agents, such as ketoconazole.
This MoA is the cornerstone of its efficacy across a vast spectrum of fungal pathogens.
Itraconazole Dosage and Administration
For those involved in manufacturing capsules, tablets, oral solutions, or compounding alternative dosage forms, knowledge of the approved dosing regimens is non-negotiable.
Table: Common Itraconazole Dosing
| Infection Type | Recommended Dosage Regimen | Duration / Notes |
|---|---|---|
| Onychomycosis (Pulse) | 200 mg twice daily | 1 week on, 3 weeks off. 2 pulses for fingernails, 3 for toenails. |
| Onychomycosis (Continuous) | 200 mg once daily | 3 months |
| Blastomycosis/Histoplasmosis | 200 mg once daily (may increase to 200 mg BID) | ≥ 3 months |
| Aspergillosis | 200 mg once daily (may increase to 200 mg BID) | 2-5 months |
| Oropharyngeal Candidiasis | 100 mg once daily (Oral Solution) | 15 days |
| Vulvovaginal Candidiasis | 200 mg twice daily | 1 day |
Critical Considerations for Industry:
Food Effect: The absorption of the capsule formulation is significantly enhanced by food and a low gastric pH. Administration with a meal or an acidic beverage (e.g., cola) is recommended. It is a critical point for patient counseling and labeling.
Bioavailability: The oral solution has higher bioavailability than the capsule and does not require gastric acid for absorption, making it preferable for patients with achlorhydria or those on acid-suppressive therapy.
Half-life: Itraconazole has a long terminal half-life (~30-40 hours) due to extensive tissue distribution. It supports once-daily dosing and contributes to its post-antifungal effect.
Itraconazole Precautions and Drug Interactions
Precautions:
Cardiac Effects: Itraconazole can cause a dose-related adverse inotropic effect, potentially leading to congestive heart failure (CHF). It is contraindicated in patients with evidence of ventricular dysfunction or a history of heart failure. This must be prominently displayed in all safety documentation.
Hepatic Impairment: Dose adjustment is required for patients with hepatic impairment. It impacts labeling and safety data required for regulatory filings. (See dedicated section below).
Renal Impairment: The pharmacokinetics of Itraconazole are not significantly altered in renal impairment. However, the excipient hydroxypropyl-β-cyclodextrin in the intravenous formulation accumulates in patients with renal failure; thus, the IV formulation should be avoided in patients with CrCl < 30 mL/min.
Drug Interactions:
Itraconazole is a potent inhibitor of the cytochrome P450 3A4 (CYP3A4) isoenzyme. Its profile is arguably the most critical pharmacological consideration for industry professionals, as it is the source of numerous, potentially severe, interactions.
Contraindicated Concomitant Use (Risk of Serious Adverse Events):
CYP3A4 Substrates: Drugs that prolong the QT interval: quinidine, dofetilide, pimozide. Concurrent use is absolutely contraindicated.
HMG-CoA Reductase Inhibitors: Simvastatin, lovastatin (increased risk of rhabdomyolysis).
Ergot Alkaloids: Dihydroergotamine, ergotamine.
Benzodiazepine: triazolam, midazolam orale.
Use with Extreme Caution (Requires Dose Adjustment & Monitoring):
Immunosuppressants: Cyclosporine, tacrolimus, sirolimus.
Anticoagulants: Warfarin (increased PT/INR).
Antiarrhythmics: Digoxin.
Anticonvulsants: Carbamazepine.
HIV Protease Inhibitors & NNRTIs: Complex bidirectional interactions.
A comprehensive drug interaction study is a must for any company developing a new product containing Itraconazole.
What are the side effects of Itraconazole?
Understanding the adverse event profile of Itraconazole is essential for risk management and patient counseling.
The most common adverse reactions are:
Gastrointestinal: Nausea, vomiting, diarrhea, abdominal pain, dyspepsia.
Hepatic: Transient, asymptomatic elevations in liver enzymes (ALT, AST). Severe hepatotoxicity, including liver failure and death, has occurred (see next section).
Dermatological: Rash, pruritus.
Endocrine/Metabolic: Hypokalemia, edema.
Neurological: Headache, dizziness.
Cardiovascular: Hypertension, CHF (dose-related).
The frequency and severity of these events are often dose- and duration-dependent.
For Compounding Pharmacies: You may consider combining supportive therapies to manage these side effects (e.g., electrolyte replacements for hypokalemia), making the overall treatment more tolerable.
Does Itraconazole affect the liver?
Yes, it does, and you can see from its side effects above.
Also, the product labeling in the United States for Itraconazole carries a Black Box Warning regarding this risk.
Liver injury ranges from:
Asymptomatic transaminase elevations: These are relatively common and often resolve upon discontinuation of the drug.
Symptomatic hepatitis: With symptoms like anorexia, nausea, vomiting, fatigue, abdominal pain, and dark urine.
Clinical hepatitis: Jaundice.
Fulminant hepatic failure and death: While rare, cases have been reported.
Recommendations for Monitoring:
Liver function tests (LFTs) should be performed in all patients before initiating treatment.
LFT monitoring should be continued periodically during treatment, especially for courses lasting longer than one month.
Patients must be advised to immediately report any symptoms of hepatitis (e.g., unusual fatigue, anorexia, nausea, vomiting, jaundice, dark urine, pale stools).
This risk underscores the importance of sourcing high-purity Itroconazole API from GMP-compliant manufacturers to avoid additional hepatotoxic stressors from impurities.
Itraconazole vs. Other Antifungal Medications
Positioning Itraconazole in the treatment landscape is key for marketing and educational efforts.
Table: Comparison of Key Systemic Antifungal Agents
| Medication (Class) | Key Spectrum & Differentiator | Advantage | Disadvantage |
|---|---|---|---|
| Itraconazole (Triazole) | Broad-spectrum (molds & yeasts); Oral solution available | Wide spectrum; good tissue penetration; established generic cost | Significant drug interactions; black box warning for CHF & hepatotoxicity |
| Fluconazole (Triazole) | Narrower spectrum (mainly yeasts); no mold activity | Excellent bioavailability, CNS penetration, and fewer interactions | No activity against Aspergillus or many resistant Candida spp. |
| Voriconazole (Triazole) | Broad-spectrum (including molds like Aspergillus); CNS penetration | Gold standard for invasive Aspergillosis; IV formulation | Complex PK; visual disturbances; phototoxicity; high cost |
| Ketoconazole (Imidazole) | Broad-spectrum (historical) | First oral azole | Significant toxicity (endocrine, hepatic); replaced mainly by safer triazoles |
| Terbinafine (Allylamine) | Primarily dermatophytes | Fungicidal; short duration for nail therapy; few interactions | Narrow spectrum; no activity against yeasts or molds |
| Amphotericin B (Polyene) | Broadest spectrum; fungicidal | Potent; life-saving for many systemic infections | Significant nephrotoxicity; infusion reactions |
Unique Selling Proposition for Itraconazole: It offers a balance of broad spectrum, oral bioavailability, and tissue penetration at a competitive cost due to its generic status, making it a workhorse in antifungal therapy.
Is Itraconazole safe during pregnancy?
Itraconazole is classified as an FDA Pregnancy Category C and is generally contraindicated during pregnancy.
Animal studies have shown evidence of embryotoxicity and teratogenicity at high doses.
Human data from limited case series and epidemiological studies have not shown a consistent pattern of increased risk of major congenital disabilities. Still, the data are insufficient to rule out risk.
Official Recommendations:
It is contraindicated for the treatment of onychomycosis during pregnancy.
It should only be used for severe, life-threatening systemic fungal infections in pregnant women if the potential benefit justifies the potential risk to the fetus.
It is a critical safety point that must be prominently featured in all informational and labeling materials, especially compounding pharmacies that may service obstetric populations.
How long does Itraconazole take to work on fungal infection?
The onset of action is rapid from a pharmacological perspective; however, clinical improvement depends on the type and site of the infection.
Symptomatic Relief (e.g., candidiasis): Patients may experience relief from symptoms such as itching and discomfort within a few days.
Superficial Skin Infections: Clinical improvement may be observed within 1-2 weeks; however, treatment should be continued for the full prescribed duration to prevent relapse.
Onychomycosis (Nail Infections): This is a slow and progressive process. Because the drug must penetrate the nail matrix and the nail must grow out, a visible clinical response (seeing new healthy nail growth) typically takes 3-6 months. The full therapeutic effect may not be evident until 6-9 months after completing therapy, due to the post-antifungal impact and the slow growth of the nails.
Systemic Infections: A clinical response (e.g., reduced fever, improved symptoms) may be observed within 1-2 weeks; however, treatment durations are often prolonged, lasting 3-12 months, depending on the infection and the host’s immune status.
For Marketing: Managing patient and prescriber expectations is key. Educational materials should emphasize the importance of completing courses of therapy, especially for long-term treatments such as onychomycosis.
Global Sourcing Tips for Itraconazole API
This section addresses the core pain points of API importers and manufacturers.
Verify Regulatory Status: Before sourcing, confirm the regulatory status in your target market to ensure compliance. Is the API approved? Is a Drug Master File (DMF) available and active with the relevant health authority (e.g., US FDA, EMA, PMDA)?
Supplier Qualification is Paramount: Do not prioritize cost over quality—partner with suppliers who have a proven track record of excellence.
Audit: Conduct rigorous audits (on-site or virtual) of the manufacturer’s facilities. Verify their GMP compliance (ICH Q7 guidelines). Look for suppliers with “WHO GMP approved production sites” and “25+ years of experience”.
Quality Documentation: Request and review the Certificate of Analysis (CoA), Stability Data, and the Manufacturer’s Working Cell Bank (MCB) information for the synthesis process.
Understand the Synthesis Pathway: Itraconazole synthesis is a complex process. Process A supplier’s expertise and control over their starting materials and intermediates directly impact the quality, purity, and consistency of the final API.
Purity and Impurity Profile: Scrutinize the CoA for:
Assay: Should be typically ≥ 99.0%.
Related Substances: Closely monitor specified and unspecified impurities. Ensure they are within ICH Q3A guidelines.
Residual Solvents: Must comply with ICH Q3C.
Particle Size Distribution: Critical for formulation bioavailability and blend uniformity.
Supply Chain Transparency: Ensure your supplier provides full traceability of materials. Be wary of brokers who cannot identify the original manufacturer transparently. Suppliers like Beaukev Pharma International emphasize providing “comprehensive documentation” and working with GMP-certified manufacturers.
Logistics and Storage: Itraconazole API should be stored in a cool, dry place, protected from light. Some suppliers recommend specific temperature ranges (e.g., 2°C to 8°C) for the long-term storage of certain forms. Ensure your logistics partner can provide appropriate storage and shipping conditions.
Compounding Pharmacy Guidelines for Itraconazole Formulations
Compounding pharmacies can fill a vital niche, especially for patients who cannot tolerate commercial formulations or need customized dosing.
API Source: Always use pharmaceutical-grade Itraconazole API from a GMP factory. Crushing commercial tablets introduces excipients that can interfere with stability, bioavailability, and dosing accuracy.
Excipient Compatibility: Conduct thorough research on compatibility. Standard compounding vehicles, such as suspending agents (e.g., SyrSpend SF) and preservatives, must not degrade the API. Perform stability studies for your specific formulation.
Dosage Form Considerations:
Oral Suspensions: A common choice for dose titration or pediatric use. The commercial solution uses hydroxypropyl-β-cyclodextrin as a solubilizer, which may be impractical for compounders. Alternative solubilizing agents or the creation of a suspension from micronized API powder are more common approaches.
Capsules: Allow for precise dosing and can be a good option for patients who need a dose not available commercially.
Topical Formulations: While challenging due to its low water solubility, there is interest in compounding itraconazole into creams, gels, or nail lacquers for localized treatment.
Stability and Beyond-Use Dating (BUD): Without formal stability studies, USP <795> guidelines for non-sterile compounding require a conservative BUD. For water-containing formulations, it’s typically ≤ 14 days when refrigerated. Investing in stability testing can allow you to assign a longer BUD, reducing waste and improving patient convenience.
Patient Counseling: This is paramount. Counsel patients on:
Proper storage conditions.
The importance of administration with food (for capsules) to ensure absorption.
The potential for long treatment durations and the need for adherence.
The critical importance of reporting any signs of liver damage or heart failure.
Cost-Effective Bulk Purchasing Strategies for Itraconazole API Importers
Forecast Demand Accurately: Use market data, prescription trend reports, and internal sales forecasts to predict your API needs. This allows you to negotiate from a position of knowledge and avoid costly last-minute purchases.
Establish Long-Term Agreements (LTAs): Secure your supply chain and lock in favorable pricing by negotiating LTAs with qualified manufacturers. This protects you from short-term fluctuations in market prices.
Consider Consortium Buying: If you are a smaller importer, explore forming a buying consortium with other non-competing companies to achieve volume discounts that would otherwise be unavailable.
Total Cost of Ownership (TCO): Look beyond the price per kilogram. Factor in:
Shipping and insurance costs.
Customs duties and tariffs.
Storage costs.
Costs of quality testing and validation.
A slightly higher API price from a more reliable supplier may result in a lower TCO by reducing risk, rejected batches, and supply disruptions.
Itraconazole Emerging Applications and Future Outlook
The future of Itraconazole extends beyond its antifungal roots, indicating potential new avenues for demand.
Oncology Research: Itraconazole has demonstrated anti-angiogenic and Hedgehog signaling pathway-inhibitory properties in preclinical studies. This has sparked interest in its potential as an adjunctive cancer therapy, particularly for basal cell carcinoma and certain lung cancers. While still experimental, clinical trials are ongoing.
Antiviral Activity: Some studies have explored its potential activity against certain viruses, including papillomaviruses and some picornaviruses; however, this remains firmly in the research domain.
Repurposing for Other Diseases: Its effects on cholesterol trafficking and other cellular pathways have led to investigations into its potential use for diseases such as tuberculosis and neurodegenerative disorders, although much more research is needed.
Staying informed about Phase II and III clinical trials for these indications will allow your business to anticipate potential shifts in demand.
Conclusion: Positioning in the Itraconazole Supply Chain
Itraconazole is more than just a generic API; it is a proven, powerful, and versatile weapon in the antifungal arsenal with a potentially expanding role.
For API importers, manufacturers, and compounding pharmacies, it represents a stable opportunity for revenue, patient service, and innovation.
Success in this market hinges on an unwavering commitment to quality, expertise in formulation and compounding, and strategic foresight in understanding the evolving clinical landscape.
By leveraging the detailed information in this guide, you can make data-driven decisions, mitigate supply chain risks, and ultimately become a trusted partner in the healthcare system.
The demand for high-quality Itraconazole API and its formulations remains strong, and now is the time to solidify your position in the supply chain.
Disclaimer:
This content is for informational purposes only and is intended for business-to-business communication within the pharmaceutical industry. It is not intended as medical advice. The manufacture, import, and use of Itraconazole API must comply with all applicable laws and regulations in the relevant country or region.
This blog post is informational only and does not constitute medical advice.
Always consult a healthcare professional before starting any new medication or treatment.
